Article

Secrets of the lac operon. Glucose hysteresis as a mechanism in dietary restriction, aging and disease.

Departments of Neuroscience and Geriatrics, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA.
Interdisciplinary topics in gerontology 02/2007; 35:39-68. DOI: 10.1159/000096555
Source: PubMed

ABSTRACT Elevated blood glucose associated with diabetes produces progressive and apparently irreversible damage to many cell types. Conversely, reduction of glucose extends life span in yeast, and dietary restriction reduces blood glucose. Therefore it has been hypothesized that cumulative toxic effects of glucose drive at least some aspects of the aging process and, conversely, that protective effects of dietary restriction are mediated by a reduction in exposure to glucose. The mechanisms mediating cumulative toxic effects of glucose are suggested by two general principles of metabolic processes, illustrated by the lac operon but also observed with glucose-induced gene expression. First, metabolites induce the machinery of their own metabolism. Second, induction of gene expression by metabolites can entail a form of molecular memory called hysteresis. When applied to glucose-regulated gene expression, these two principles suggest a mechanism whereby repetitive exposure to postprandial excursions of glucose leads to an age-related increase in glycolytic capacity (and reduction in beta-oxidation of free fatty acids), which in turn leads to an increased generation of oxidative damage and a decreased capacity to respond to oxidative damage, independent of metabolic rate. According to this mechanism, dietary restriction increases life span and reduces pathology by reducing exposure to glucose and therefore delaying the development of glucose-induced glycolytic capacity.

0 Followers
 · 
179 Views
  • Source
    • "Thus, ketone bodies are more efficient in producing ATP than is glucose and can stimulate mitochondrial biogenesis via the up-regulation of genes encoding energy metabolism and mitochondrial enzymes (Kashiwaya et al. 1994; Sato et al. 1995; Veech et al. 2001). In addition, metabolism of ketone bodies produces less ROS than does glucose (Mobbs et al. 2007). Our observations that ketone bodies attenuate the HIV-1 Tat-induced drop in ATP levels, decreases in mitochondrial membrane potential, increases in levels of ROS, and elevation in intracellular calcium seem to support this premise. "
    [Show abstract] [Hide abstract]
    ABSTRACT: J. Neurochem. (2012) 10.1111/j.1471-4159.2012.07764.x ABSTRACT: HIV-1-associated neurocognitive disorder (HAND) is a syndrome that ranges clinically from subtle neuropsychological impairments to profoundly disabling HIV-associated dementia. Not only is the pathogenesis of HAND unclear, but also effective treatments are unavailable. The HIV-1 transactivator of transcription protein (HIV-1 Tat) is strongly implicated in the pathogenesis of HAND, in part, because of its well-characterized ability to directly excite neurons and cause neurotoxicity. Consistent with previous findings from others, we demonstrate here that HIV-1 Tat induced neurotoxicity, increased intracellular calcium, and disrupted a variety of mitochondria functions, such as reducing mitochondrial membrane potential, increasing levels of reactive oxygen species, and decreasing bioenergetic efficiency. Of therapeutic importance, we show that treatment of cultured neurons with ketone bodies normalized HIV-1 Tat induced changes in levels of intracellular calcium, mitochondrial function, and neuronal cell death. Ketone bodies are normally produced in the body and serve as alternative energy substrates in tissues including brain and can cross the blood-brain barrier. Ketogenic strategies have been used clinically for treatment of neurological disorders and our current results suggest that similar strategies may also provide clinical benefits in the treatment of HAND.
    Journal of Neurochemistry 04/2012; 122(2). DOI:10.1111/j.1471-4159.2012.07764.x · 4.24 Impact Factor
  • Source
    • "Since hypothalamic responses to glucose are mediated by glucose metabolism (Yang et al., 1999; Cheng et al., 2008), we examined effects of estradiol on hypothalamic expression of genes regulating glucose metabolism (Mobbs et al., 2007). This analysis indicated that estradiol inhibited hypothalamic (but not heptic) expression of CPT1a and PDK4 (Fig.5) both of which normally act to reduce glucose metabolism (Mobbs et al., 2007). These results suggest that at least one mechanism by which estradiol attenuates hypothalamic responses to hypoglycemia is by increasing hypothalamic glucose metabolism. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In rats and humans estradiol attenuates neuroendocrine responses to hypoglycemia. Since neuroendocrine responses to hypoglycemia are mediated by hypothalamic neurons, we assessed if estradiol attenuates hypoglycemia-induced gene expression in the hypothalamus in female ovariectomized mice. As expected, estradiol-implanted ovariectomized mice exhibited increased plasma estradiol, increased uterine weight, decreased body weight, decreased visceral adiposity, and enhanced glucose tolerance with decreased plasma insulin. Estradiol-implanted mice exhibited attenuated hypoglycemia-induced gene expression of both glucose transporter 1 (Glut1) and inhibitor of kappa beta signaling (IkappaB) in the hypothalamus but not in the liver. Estradiol also attenuated hypoglycemia-induced plasma glucagon, pituitary proopiomelanocortin (POMC), and adrenal c-fos, consistent with impaired counterregulatory responses to hypoglycemia. In addition, estradiol inhibited hypothalamic expression of carnitine palmitoyltransferase (CPT1a and CPT1c) and pyruvate dehydrogenase kinase 4 (PDK4), effects that would be expected to enhance the accumulation of long-chain fatty acids and glycolysis. Taken together, these findings suggest hypothalamic mechanisms mediating attenuation of hypoglycemia-induced neuroendocrine responses.
    Brain research 06/2009; 1280:77-83. DOI:10.1016/j.brainres.2009.05.017 · 2.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although the pathophysiology of neurodegenerative diseases is distinct for each disease, considerable evidence suggests that a single manipulation, dietary restriction, is strikingly protective against a wide range of such diseases. Thus pharmacological mimetics of dietary restrictions could prove widely protective across a range of neurodegenerative diseases. The PPAR transcription complex functions to re-program gene expression in response to nutritional deprivation as well as in response to a wide variety of lipophilic compounds. In mammals there are three PPAR homologs, which dimerize with RXR homologs and recruit coactivators Pgc1-alpha and Creb-binding protein (Cbp). PPARs are currently of clinical interest mainly because PPAR activators are approved for use in humans to reduce lipidemia and to improve glucose control in Type 2 diabetic patients. However, pharmacological enhancement of the activity of the PPAR complex is neuroprotective across a wide variety of models for neuropathological processes, including stroke, Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. Conversely activity of the PPAR transcriptional complex is reduced in a variety of neuropathological processes. The main mechanisms mediating the neuroprotective effects of the PPAR transcription complex appear to be re-routing metabolism away from glucose metabolism and toward alternative subtrates, and reduction in inflammatory processes. Recent evidence suggests that the PPAR transcriptional complex may also mediate protective effects of dietary restriction on neuropathological processes. Thus this complex represents one of the most promising for the development of pharmacological treatment of neurodegenerative diseases.
    09/2012; 3(3). DOI:10.2478/s13380-012-0035-8
Show more